



Expressions for Healthv Life

Press Note

April 30, 2013

## **Intas launches “Mabtas”, its biosimilar version of Rituximab**

Cancer care is costly. It drains families emotionally and financially. With a view to make Non-Hodgkin's Lymphoma (NHL) treatment cost-effective, Intas Pharmaceuticals Limited has launched “Mabtas” in India. Mabtas is a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis apart from NHL.

Mabtas is manufactured in the state of the art, Asia’s only EU GMP facility of Intas Biopharmaceuticals, Ahmedabad. With the launch of this product, Intas now is the only company to have indigenously developed 6 biosimilars in the domestic market. Intas Biopharmaceuticals is India's first and only biopharmaceutical companies to receive European Union - Good Manufacturing Practice (EU-GMP) certification for its microbial manufacturing facility and only company having product under-registration with EMA. Intas Biopharmaceuticals is already a leading manufacturer of Erythropoietin, G-CSF and peg G-CSF for India and have introduced world’s first biosimilar peg G-CSF. Mabtas marks the first monoclonal antibody (mAb) launch from Intas. With this product Intas joins the ranks of select few Indian companies to launch a mAb product in the domestic market.

Intas is a leading multi-specialty Pharmaceutical company committed to deliver affordable and innovative pharmaceutical solutions. The company is now the 12th largest pharmaceutical company in the domestic market (as per IMS Health India, Secondary Stockist Audit (SSA), January, 2013). Intas is one of the leading players in chronic therapy in domestic market. Its portfolio extends to central nervous system (CNS), cardiovascular system (CVS), oncology, diabetes, gastroenterology, pain management, urology, nephrology, gynecology, infertility and respiratory care. Intas also has its extensive presence in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, South Africa, Australia and New Zealand among others.